UCB - Sales Revenues


UCB reported EUR4.25B in Sales Revenues for its fiscal semester ending in December of 2025.





Sales Change Date
Alcon AG USD 2.72B 60M Sep/2026
Almirall EUR 602.71M 55.09M Jun/2026
Amarin USD 49.22M 451K Dec/2025
argenx SE USD 1.72B 361M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Bayer EUR 10.05B 820M Sep/2026
Genmab DKK 1.16B 259M Jun/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
GRIFOLS EUR 2.04B 170M Sep/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lakefront Biotherapeutics EUR 7.11M 5M Sep/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.63B 200M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Orion EUR 542.2M 20.6M Sep/2026
Recordati EUR 672M 9.35M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
UCB EUR 4.25B 764M Dec/2025
Unibail Rodamco EUR 1.49B 77M Dec/2025